|
Pre-Filled Syringes and Related Systems: World Market Outlook 2010-2025
|
|||||||||||
| Caracteristicas de este estudio de mercado: |
This report gives you the following benefits in particular: 199 seiten | |||||||||||
| Sobre este articulo de mercado: |
The market for pre-filled syringes has achieved growth in recent years. In 2009, an estimated 2 billion pre-filled syringe units were sold and the market for that technology was estimated to be worth .....
The market for pre-filled syringes has achieved growth in recent years. In 2009, an estimated 2 billion pre-filled syringe units were sold and the market for that technology was estimated to be worth up to $2.5 billion. There is a trend towards pre-filled drug injection systems, away from vials/ampules, for both new and existing products. Examples are filled glass and plastic syringes, pens and low-volume auto-injection devices, including refills. That sector has shown growth of 10-15% in recent years, forming one of the fastest-expanding sectors in the pharmaceutical industry. In our new report, we predict that the pre-filled drug delivery market will grow steadily from 2010, as the number of products launched in pre-filled injectable forms increases. Medical professionals, patients and other stakeholders see the benefits of that more-convenient system, raising demand at the expense of older formats. Pre-Filled Syringes and Related Systems: World Market Outlook 2010-2025 shows how a range of therapeutic agents – vaccines, insulins, analogues and many other biologicals – drive growth in that sector. Combined with new pre-filled drug delivery systems and healthcare safety and cost-saving initiatives, the market for pre-filled syringes and similar devices will expand steadily. All the therapeutic segments using pre-filled injectables have been growing in revenue, but which will expand fastest in future? What are the therapeutic and commercial trends to watch? How will the global market for pre-filled syringe-type products perform from 2010 to 2025? Our report answers such questions, providing the information that you need. The range of pre-filled syringes and related products has broadened into many areas, including: • Vaccines • Anti-coagulants • Anti-infectives • Anti-inflammatory agents • Haematological agents • Multiple sclerosis therapies • Hormone therapies • Obstetric agents • Cancer therapies • Pain relievers. The pharmaceutical industry accepts pre-filled drug technology as a proven market and the format of choice for many parentally-administered drugs. Because a product’s delivery system can affect patient compliance – influencing therapeutic outcomes, cost-effectiveness and brand image – easier-to-use devices can confer higher sales and market share. Our new report shows how partnerships between companies will be crucial when developing and harnessing pre-filled injection technologies. Detailed analysis of the pre-filled drug delivery industry and market Pre-Filled Syringes and Related Systems: World Market Outlook 2010-2025 examines that sector through a comprehensive review of information sources. We use primary and secondary research. This report provides unique sales forecasts, market share analyses, discussions of R&D pipeline developments and analyses of commercial drivers and restraints, including SWOT analysis. There are over 110 tables and figures included, as well as two interviews with experts. The result is a comprehensive market- and industry-centred study, with detailed analyses and informed opinion to benefit your work. This primary research is not available anywhere else - so to benefit from this you must read this report. Report Highlights Companies Listed Abbott Laboratories Albert David Alkermes Alshifa Medical Syringes Manufacturing Company Althea Technologies Amgen Amylin Pharmaceuticals AstraZeneca Avitro B. Braun Medical Battelle Medical Device Solutions Baxter International BD Biosciences BD Healthcare Consulting & Services (BDHCS) BD Pharmaceutical Systems Becton, Dickinson & Co. Biogen Idec Inc. Bioject Medical Technologies Biopartners Boston Scientific Corp. Disetronic Group C. R. Bard. Cambridge Antibody Technology (now a part of AstraZeneca) Cambridge Consultants Catalent Pharma Solutions Centers for Disease Control and Prevention (CDC), [US] Centocor Ortho Biotech Chugai Pharmaceutical (a subsidiary of Roche Holding AG.) Coeur Covidien Daikyo Seiko Disetronic Holding Dongbao Eisai Eli Lilly European Medicines Agency (EMEA) European Society for Medical Oncology Flamel Technologies Food and Drug Administration (FDA) [US] Genentech Gerresheimer GlaxoSmithKline Henke-Sass Wolf Hindustan Syringes and Medical Devices Hi-Tech Medical Products Hyaluron Contract Manufacturing Immunex International Medication Systems Johnson & Johnson Life-Shield Products Medex Merck & Co. Merck Serono Merit Medical Systems MG Sterile Products MGlas Milestone Scientific Ministry for Health, Labor and Welfare (Japan) National Health Service (NHS), [UK] Novartis Novo Nordisk Nycomed Occupational Safety and Health Administration (OSHA), [US] Otsuka Pharmaceutical Owen Mumford Pfizer Pharmaceutical Research & Manufacturers of America (PhRMA), [US] Plas-Pak Industries PRC State Food and Drug Administration [China] Protalix BioTherapeutics Ratiopharm Retractable Technologies Revolutions Medical Corporation Roche Holding Royal College of Nursing (RCN) [UK] Safety Syringes Sanofi Pasteur sanofi-aventis Schering-Plough SCHOTT Shanghai Celgen Bio-Pharmaceutical Co. Smiths Medical International Specialised Health Products International Star Syringe Takeda Pharmaceuticals Co. Terumo Medical Corporation UCB UltiMed Unilife Medical Solutions Vetter Pharma International Vetter Pharma-Fertigung Vita Needle Company West Pharmaceutical Services World Health Organisation (WHO) Wuxi Yushou Medical Appliances Co. Wyeth Pharmaceuticals (now part of Pfizer) Ypsomed Holding [Cerrar las informaciones del articulo de mercado] |
|||||||||||
|
1. Executive Summary 1.1 Pre-Filled Syringes Market Review 1.2 Aims, Scope and Format of the Report 1.3 Research & Analysis Methods 2. Introduction to Pre-Filled Syringes 2.1 The Pre-Filled Syringe Market 2.1.1 Market Overview 2.1.2 Increasingly Alluring Sector 2.1.3 Greater Prevalence of Pre-Filled Syringes 2.1.4 Pre-Filled Syringes: The Current Situation 2.2 Introduction to Syringe Technology 2.2.1 Brief Historical Perspective 2.3 The Design and Construction of Pre-Filled Syringes 2.3.1 Pre-Filled Syringe Components 2.3.2 Silicone and Biotechnology Products 2.3.3 Material Choice: Glass or Plastic? 2.3.4 Syringe Operation: Manual vs. Mechanical 2.3.5 Pharmaceutical Development: Extractables, Leachables and Manufacturing Residuals 2.3.6 Pharmaceutical Development: Functional Testing of Delivery Systems 2.4 Pre-Filled Syringes Offer Convenience Over Alternatives 2.4.1 Pre-Filled Syringes for Lyophilized Drugs 2.5 Needle Stick Injuries and the Drive Towards Pre-Filled Syringes 2.5.1 Blood-Borne Pathogens and Needle Stick Injury 2.5.2 Accidental Needle Stick Injuries: a Healthcare Problem 2.6 Injection Delivery Devices 2.6.1 Pen Injectors 2.6.2 Insulin Pens 2.6.3 Auto-Injectors 2.6.4 Needle-Free Injectors 2.6.5 Selection of Injection Devices 3. The World Pre-Filled Syringes Market, 2010-2025 3.1 The World Pre-Filled Syringes Market in 2010 3.2 Growing Market for Pre-Filled Syringes 3.2.1 Sales Forecast for Pre-Filled Syringe Units, 2010-2016 3.2.2 Sales Forecast for Pre-Filled Syringe Units, 2017-2025 3.2.3 Sales Forecast for Pre-Filled Syringes Market, 2010-2016 3.2.4 Sales Forecast for Pre-Filled Syringes Market, 2017-2025 3.3 Therapeutic Areas Offering Growth Opportunities 3.3.1 The Leading Biotech Therapy Classes, 2010-2025 3.3.2 The Top 10 Biotech Therapy Classes in 2009 3.3.3 The Oncology Class Currently Leads the Biotech Market 3.3.3.1 Long-Term Prospects in Oncology & Implications for Pre-Filled Syringes Market 3.3.4 The Human Insulins Class will Exhibit Strong Growth. 3.3.5 Immunosuppressive Agents, 2010-2025 3.3.6 Autoimmune Agents Show Promising Growth – Will it Last? 3.3.7 Erythropoietin Products - How will Reported Safety Affect Sales? 3.3.7.1 Erythropoietin Products: Market Forecast, 2010-2025 3.3.8 Immunostimulating Agents – Sales Prospects 3.3.9 The Interferons Class will Show an Increase in Revenues from 2010-2015 3.3.9.1 Long-Term Forecast for the Interferons Class 3.3.10 Pure Vaccines – Near Term Sales Prospects 3.3.10.1 Will Pure Vaccine Sales Continue to Decline After 2015? 3.3.11 Blood Coagulation Factors – Sales Prospects 3.3.12 Growth Hormones Forecast, 2010-2025 3.4 Summary of World Market Forecasts 3.4.1 The Top 10 Biotech Therapy Classes, 2010-2025 3.4.2 Pre-Filled Syringe Market – a Rapidly Expanding Segment 3.5 Leading Pre-Filled Syringe Country Markets, 2010-2025 3.5.1 The US Pre-Filled Syringe Market, 2010-2025 3.5.2 The Japanese Pre-Filled Syringe Market, 2010-2025 3.5.3 The Leading European Pre-Filled Syringe Markets, 2010-2025 3.5.4 Emerging Economy Pre-Filled Syringe Markets 3.5.5 The Chinese Pre-Filled Syringe Market, 2010-2025 3.5.6 The Indian Pre-Filled Syringe Market, 2010-2025 4. Leading Companies in the Pre-Filled Syringe Field 4.1 Introduction 4.2 Becton, Dickinson and Company (BD) 4.2.1 Overview 4.2.2 Global Presence 4.2.3 Distribution 4.2.4 Focus on Parenteral & BioMaterial Technologies 4.2.5 Products 4.2.5.1 BD Hypak SCF Syringe Systems 4.2.5.2 BD Sterifill SCF Syringe Systems 4.2.5.3 Self-Injection Systems 4.2.5.3.1 BD Physioject Disposable AutoInjector 4.2.5.3.2 BD MicroInfusor Automatic Injection System 4.2.5.3.3 BD Liquid Dry Injector Disposable Pen Injector 4.2.5.3.4 BD Pens 4.2.5.4 Detachable and Integrated Safety Systems 4.2.5.5 BD Soluvia Pre-Fillable Microinjection System 4.2.5.6 BD Uniject SCF: Auto-Disable Injection System 4.2.6 R&D 4.2.7 Revenues 4.3 Vetter Pharma-Fertigung 4.3.1 Overview 4.3.2 Global Presence 4.3.3 Business Interests 4.3.3.1 Vetter Development Service 4.3.3.2 Vetter Commercial Manufacturing 4.3.3.3 Vetter Solutions 4.3.4 Capabilities 4.3.5 R&D 4.3.6 Product Focus 4.3.6.1 Dual-Chamber Technology 4.3.6.2 Single-Chamber Syringes and Cartridges 4.3.7 Revenues 4.4 SCHOTT 4.4.1 Overview 4.4.2 Global Presence 4.4.3 SCHOTT's Pharmaceutical Systems 4.4.4 SCHOTT's Pharmaceutical Packaging Business Segment 4.4.5 Products: Pre-Fillable Polymer Syringes 4.4.5.1 SCHOTT TopPac Pre-Fillable Syringes 4.4.5.2 SCHOTT InJentle: Innovative Staked Needle Syringe 4.4.6 Revenues 4.5 Abbott Laboratories 4.5.1 Overview 4.5.2 Market Areas and Products 4.5.3 Pre-Filled Syringe Products: Humira 4.5.4 Abbott's Other Syringe Products 4.5.4.1 Abbott Abboject 4.5.4.2 Abbott LifeShield 4.5.4.3 Abbott Ansyr 4.5.4.4 Abbott Carpuject Injector 4.5.5 Revenues 4.6 Ypsomed 4.6.1 Overview 4.6.2 Global Presence 4.6.3 Products 4.6.3.1 Insulin Pen Injectors 4.6.3.2 Pen Injectors for Other Indications 4.6.3.3 Monodose Pens for Dual-Chamber Cartridges 4.6.3.4 Disposable Auto-Injectors 4.6.3.5 Standard Pen Needles Penfine and Clickfine 4.6.3.6 Safety Pen Needle Clickfine AutoProtect 4.6.4 R&D 4.6.5 Revenues 4.6.6 Future Outlook 4.7 Gerresheimer 4.7.1 Overview 4.7.2 Business Operations 4.7.3 Locations 4.7.4 Gerresheimer's Tubular Glass Division 4.7.5 Syringe Systems 4.7.5.1 Technology Centre for Syringe Systems 4.7.5.2 Technical Competence Centre for Plastic Products 4.7.6 Revenues 4.7.7 R&D 4.7.8 Outlook 4.8 MGlas (MG) 4.8.1 Overview 4.8.2 Products 4.8.2.1 Pre-Fillable Syringes/Cartridges/Vials 4.8.2.2 MG Innovative Needles 5. Leading Pre-Filled Syringe Products on the Market 5.1 Introduction 5.2 Insulins and Antidiabetic Agents 5.2.1 Leading Human Insulins and Analogues 5.2.1.1 Lantus 5.2.1.2 Novorapid 5.2.1.3 Humalog 5.2.1.4 Novomix 5.2.1.5 Levemir 5.2.1.6 Actraphane HM 5.3 Byetta/Exenatide LAR 5.3.1 Byetta's Strengths 5.3.2 Restraints on Byetta 5.4 Leading Biotech Products in Pre-Filled Syringe Format 5.4.1 Enbrel 5.4.1.1 Enbrel Currently Leads the Global Biotech Market 5.4.1.2 Enbrel Will Show an Initial Increase in Sales 5.4.1.3 Study Eases Fears of TNF Blocker Cancer Risk 5.4.1.4 New Enbrel Delivery System 5.4.1.5 Enbrel Lifecycle Management 5.4.1.6 Sales of Enbrel – Eventual Decline 5.4.1.7 Enbrel Faces Competition from Other Biotech Drugs 5.4.1.8 Competition from Biosimilars? 5.4.2 Avastin 5.4.2.1 Avastin Will Show High Growth – But Will it Last? 5.4.2.2 New Avastin Drug Delivery Method for Treatment of Brain Tumours 5.4.3 Humira 5.4.3.1 Humira – 2009's Fastest Growing Biotech Drug 5.4.3.2 Humira Market Forecast, 2010-2015 5.4.3.3 Long-Term Prospects for Humira 5.4.4 Lantus 5.4.4.1 Lantus Will Show an Initial Increase in Sales 5.4.4.2 Will Lantus Sales Continue to Increase? 5.4.5 Neulasta 5.4.5.1 Neulasta Sales Forecast, 2010-2025 5.5 Other Pre-Filled Drugs on the Market 5.5.1 Avonex 5.5.1.1 Avonex Market Forecast, 2010-2025 5.5.1.2 Avonex Faces Competition from New Oral MS Drugs 5.5.2 Rebif 5.5.2.1 Rebiject II 5.5.2.2 RebiSmart 5.5.2.3 Rebif Sales Forecast, 2010-2015 5.5.2.4 Rebif Sales Forecast, 2015-2025 6. Factors Influencing the Pre-Filled Syringes Industry and Market 6.1 Introduction 6.2 Commercial Drivers of the Pre-Filled Syringes Market 6.2.1 Cost Savings – a Powerful Motivator? 6.2.2 Glass Pre-Fillable Syringes 6.2.3 Plastic Pre-Fillable Syringes 6.2.4 Convenience & Safety Issues 6.2.5 Cost Efficiencies 6.2.6 Product Differentiation and Customization 6.2.7 Reimbursement 6.3 Commercial Restraints for the Pre-Filled Syringes Market 6.3.1 Pre-Filled Syringe Systems Have Limitations 6.3.2 Patients Prefer Pills 6.4 Emerging Trends and Opportunities in the Pre-Filled Syringes Market: Opportunity Analysis 6.5 Challenges Facing the Pre-Filled Syringes Market 6.5.1 Needle Stick Safety & Prevention Laws 6.5.1.1 Compliance with Needle Stick Safety & Prevention Laws 6.5.1.2 Key Findings Leading to the Legislation 6.5.1.3 Increasing Exposure to Blood-Borne Pathogens 6.5.1.4 OSHA 1991 Regulation Standard 6.5.1.5 CDC Estimates Over Half Million Needle Stick and Other Percutaneous Injuries Annually 6.5.1.6 Newer Engineering Controls & Safer Medical Devices 6.5.1.7 CDC Estimates 80% Sharps Injuries Preventable 6.5.1.8 OSHA 200 Log Surveillance System 6.5.1.9 Training and Education 6.5.1.10 Summary of Regulatory and Legislative Requirements 6.5.2 State-Level OSHA Plans and Federal Legislation 6.5.3 BPS Enforcement by OSHA 6.5.4 Laws in Other International Markets 6.5.5 EU on the Brink of New Laws to Tackle Needle Stick Injuries 6.5.6 High Entry Barriers, Few Suppliers 6.5.7 Product Stability a Concern 6.5.7.1 Leachables and Safety 6.5.7.2 Compatibility between Drug Product and Pre-Filled Syringes 6.5.7.3 Eprex and Leaching 6.5.7.4 Protein Aggregation Related to Leached Tungsten 6.5.7.5 Protein Aggregation Related to Silicon Oil 6.5.8 Product Stability and Quality Assurance Programme 6.5.8.1 Paediatric H1N1 Vaccine Manufactured by Sanofi Pasteur in Pre-Filled Syringes Recalled from the Market 6.5.8.2 Novartis Voluntarily Withdrew Five Lots of Fluvirin Flu Vaccine 6.5.8.3 Shelf Life of Some H1N1 Vaccine Batches Changed 6.5.8.4 Contamination Problems with Leachables in Pre-Fillable Syringes 6.5.8.5 West and Daikyo Offer Syringe Systems to Minimise Leaching 6.5.8.6 SCHOTT AG Launched InJentle Syringe to Improve Drug Stability 6.6 Conclusions 7. Expert Views from the Sector 7.1 Expert Interview 1: Dr Phil Lever, Commercial Director, Cambridge Consultants, Cambridge, UK 7.1.1 Current Market Valuation for Pre-Filled Syringes 7.1.2 Key Unmet Needs 7.1.3 Research and Development 7.1.4 Problems with the Current Use of Pre-Filled Syringes 7.1.5 Advantages of Pre-Filled Syringes over Other Modes of Drug Delivery 7.1.6 Drawbacks of Pre-Filled Syringes 7.1.7 Key Challenges: Technologies and Strategies for the Development of Pre-Filled Devices 7.1.8 Complexities for Making New Pre-Filled Syringes 7.1.9 Preferred Component Materials, Surface Treatments and Filling Processes 7.1.10 Technologies, Developments and R&D 7.1.11 Main Therapeutic Areas Offering Growth Opportunities 7.1.12 The Future of Pre-Filled Syringes in the Next Decade 7.1.13 Main Threats Facing PFS Industry 7.1.14 Novel Technology/Developments 7.1.15 Potential Replacement 7.2 Expert Interview 2: Authority from a Company in the Sector (Views Provided Anonymously) 7.2.1 Unmet Needs and Market for Pre-Filled Syringes 7.2.2 Competing Products and Alternatives to Pre-Filled Syringes 7.2.3 Disadvantages and Drawbacks with Pre-Filled Syringes and Devices 7.2.4 Pre-Filled Syringe Products, Safety and Vaccines 7.2.5 Challenges for Complex Biological Therapeutics in Pre-Filled Syringes 7.2.6 Versatility of Pre-Filled Syringes 7.2.7 Dual-Chamber Pre-Filled Syringe Systems 7.2.8 Syringe Material: Glass vs. Plastic 7.2.9 Future Developments in Pre-Filled Syringe Systems 7.2.10 Progress in Needle Stick Injury (NSI) Legislation for Europe 7.2.11 NSI Legislation and Implications for Stakeholders 8. Conclusions: Pre-Filled Syringe Systems are a Growth Market 8.1 Introduction 8.2 Leading Players in the Market 8.3 Commercial Drivers of the Pre-Filled Syringe Market 8.4 Future Outlook 8.4.1 Further Advances? 8.4.2 Future Developments in Pre-Filled Syringe Systems 8.5 Concluding Remarks [Cerrar la tabla de contenidos] |
||||||||||||
|
Table 2.1 Summary of Drivers for Growth in the Pre-Filled Syringes Market, 2010 Table 2.2 Historical Timeline for Development of Syringe Technology Table 2.3 Components of Pre-Fillable Syringes Table 2.4 Leading Brands of Insulin in Pen Syringe Format, 2009 Table 2.5 Main Factors Increasing the Interest in Auto-Injectors, 2010 Table 3.1 Pre-Filled Syringes: World Unit Sales Forecast, 2010-2016 Table 3.2 Pre-Filled Syringes: World Unit Sales Forecast, 2017-2025 Table 3.3 Pre-Filled Syringes: World Sales Forecast, 2010-2016 Table 3.4 Pre-Filled Syringes: World Sales Forecast, 2017-2025 Table 3.5 The Top 10 Biotech Therapy Classes, 2009 Table 3.6 Oncology Class: World Sales Forecast, 2010-2016 Table 3.7 Oncology Class: World Sales Forecast, 2017-2025 Table 3.8 Human Insulins Class: World Sales Forecast, 2010-2016 Table 3.9 Human Insulins Class: World Sales Forecast, 2017-2025 Table 3.10 Immunosuppressive Agents Class: World Sales Forecast, 2010-2016 Table 3.11 Immunosuppressive Agents Class: World Sales Forecast, 2017-2025 Table 3.12 Autoimmune Agents Class: World Sales Forecast, 2010-2016 Table 3.13 Autoimmune Agents Class: World Sales Forecast, 2017-2025 Table 3.14 Erythropoietin Products Class: World Sales Forecast, 2010-2016 Table 3.15 Erythropoietin Products Class: World Sales Forecast, 2017-2025 Table 3.16 Immunostimulating Agents Class: World Sales Forecast, 2010-2016 Table 3.17 Immunostimulating Agents Class: World Sales Forecast, 2017-2025 Table 3.18 Interferons Class: World Sales Forecast, 2010-2016 Table 3.19 Interferons Class: World Sales Forecast, 2017-2025 Table 3.20 Pure Vaccines Class: World Sales Forecast, 2010-2016 Table 3.21 Pure Vaccines Class: World Sales Forecast, 2017-2025 Table 3.22 Blood Coagulation Factors Class: World Sales Forecast, 2010-2016 Table 3.23 Blood Coagulation Factors Class: World Sales Forecast, 2017-2025 Table 3.24 Growth Hormones Class: World Sales Forecast, 2010-2016 Table 3.25 Growth Hormones Class: World Sales Forecast, 2017-2025 Table 3.26 Leading Biotech Therapy Classes: World Sales Forecasts, 2010-2016 Table 3.27 Leading Biotech Therapy Classes: World Sales Forecasts, 2017-2025 Table 3.28 Leading Pre-Filled Syringe National Market Forecasts, 2010-2015, 2020 & 2025 Table 4.1 Leading Companies in Pre-Filled Syringes Market, 2010 Table 5.1 Anti-Diabetic Agents Available in Pre-Filled Syringe Format, 2010 Table 5.2 Lantus: World Sales Forecast, 2010-2016 Table 5.3 Lantus: World Sales Forecast, 2017-2025 Table 5.4 Novorapid: World Sales Forecast, 2010-2016 Table 5.5 Novorapid: World Sales Forecast, 2017-2025 Table 5.6 Humalog: World Sales Forecast, 2010-2016 Table 5.7 Humalog: World Sales Forecast, 2017-2025 Table 5.8 Novomix: World Sales Forecast, 2010-2016 Table 5.9 Novomix: World Sales Forecast, 2017-2025 Table 5.10 Levemir: World Sales Forecast, 2010-2016 Table 5.11 Levemir: World Sales Forecast, 2017-2025 Table 5.12 Actraphane: World HM Sales Forecast, 2010-2016 Table 5.13 Actraphane: World HM Sales Forecast, 2017-2025 Table 5.14 Byetta: World Sales Forecast, 2010-2016 Table 5.15 Byetta: World Sales Forecast, 2017-2025 Table 5.16 Six of the Top Ten Biotech Drugs Marketed as PFS Products, 2009 Table 5.17 Enbrel: World Sales Forecast, 2010-2016 Table 5.18 Enbrel: World Sales Forecast, 2017-2025 Table 5.19 Avastin: World Sales Forecast, 2010-2016 Table 5.20 Avastin: World Sales Forecast, 2017-2025 Table 5.21 Humira: World Sales Forecast, 2010-2016 Table 5.22 Humira: World Sales Forecast, 2017-2025 Table 5.23 Lantus: World Sales Forecast, 2010-2016 Table 5.24 Lantus: World Sales Forecast, 2017-2025 Table 5.25 Neulasta: World Sales Forecast, 2010-2016 Table 5.26 Neulasta: World Sales Forecast, 2017-2025 Table 5.27 Avonex: World Sales Forecast, 2010-2016 Table 5.28 Avonex: World Sales Forecast, 2017-2025 Table 5.29 Rebif: World Sales Forecast, 2010-2016 Table 5.30 Rebif: World Sales Forecast, 2017-2025 Table 5.31 Some Leading Pre-Filled Syringe Vaccine Products on Market, 2010 Table 6.1 SWOT Analysis for World Pre-Filled Syringes Market: Strengths, 2010-2025 Table 6.2 SWOT Analysis for World Pre-Filled Syringes Market: Weaknesses, 2010-2025 Table 6.3 SWOT Analysis for World Pre-Filled Syringes Market: Opportunities & Threats, 2010-2025 Table 6.4 Risk of Infection Following Needle Stick Incident, 2010 Table 6.5 Examples of Leachables Impacting on Safety and Product Quality Table 8.1 Pre-Filled Syringes: World Unit Sales Forecast, 2010, 2012, 2015, 2018, 2020 and 2025 Table 8.2 Pre-Filled Syringes: World Sales Forecast, 2010, 2012, 2015, 2018, 2020 and 2025 Figure 3.1 Pre-Filled Syringes: World Unit Sales Forecast, 2010-2016 Figure 3.2 Pre-Filled Syringes: World Unit Sales Forecast, 2017-2025 Figure 3.3 Pre-Filled Syringes Market: World Sales Forecast, 2010-2016 Figure 3.4 Pre-Filled Syringes Market: World Sales Forecast, 2017-2025 Figure 3.5 Oncology Class: World Sales Forecast, 2010-2025 Figure 3.6 Human Insulins Class: World Sales Forecast, 2010-2025 Figure 3.7 Immunosuppressive Agents Class: World Sales Forecast, 2010-2025 Figure 3.8 Autoimmune Agents Class: World Sales Forecast, 2010-2025 Figure 3.9 Erythropoietin Products Class: World Sales Forecast, 2010-2025 Figure 3.10 Immunostimulating Agents Class: World Sales Forecast, 2010-2025 Figure 3.11 Interferons Class: World Sales Forecast, 2010-2025 Figure 3.12 Pure Vaccines Class: World Sales Forecast, 2010-2025 Figure 3.13 Blood Coagulation Factors Class: World Sales Forecast, 2010-2025 Figure 3.14 Growth Hormones Class: World Sales Forecast, 2010-2025 Figure 3.15 Leading Biotech Therapy Classes: World Sales Forecast, 2010-2025 Figure 3.16 Top Ten Therapy Classes: World Sales, 2009, 2015 & 2025 Figure 3.17 US Pre-Filled Syringe Market Forecast, 2010-2025 Figure 3.18 Other Leading Pre-Filled Syringe National Market Forecasts, 2010-2025 Figure 3.19 Pre-Filled Syringe Sales in Leading National Markets 2010 Figure 3.20 Pre-Filled Syringe Sales in Leading National Markets 2015 Figure 3.21 Pre-Filled Syringe Sales in Leading National Markets 2020 Figure 3.22 Pre-Filled Syringe Sales in Leading National Markets 2025 Figure 4.1 BD Sales Revenues: Fiscal Year, 2009 Figure 4.2 SCHOTT Sales Revenues by Region, 2007-2008 Figure 4.3 Distribution of Gerresheimer Workforce, 2009-2010 Figure 4.4 Gerresheimer Sales by Division, 2009 Figure 4.5 Gerresheimer Sales by Region, 2009 Figure 5.1 Lantus: World Sales Forecast, 2010-2025 Figure 5.2 Novorapid: World Sales Forecast, 2010-2025 Figure 5.3 Humalog: World Sales Forecast, 2010-2025 Figure 5.4 Novomix: World Sales Forecast, 2010-2025 Figure 5.5 Levemir: World Sales Forecast, 2010-2025 Figure 5.6 Actraphane HM: World Sales Forecast, 2010-2025 Figure 5.7 Byetta: World Sales Forecast, 2010-2025 Figure 5.8 Enbrel: World Sales Forecast, 2010-2025 Figure 5.9 Avastin: World Sales Forecast, 2010-2025 Figure 5.10 Humira: World Sales Forecast, 2010-2025 Figure 5.11 Lantus: World Sales Forecast, 2010-2025 Figure 5.12 Neulasta: World Sales Forecast, 2010-2025 Figure 5.13 Avonex: World Sales Forecast, 2010-2025 Figure 5.14 Rebif: World Sales Forecast, 2010-2025 Figure 6.1 Preferences for Pre-Filled Syringes by Healthcare Professionals Figure 8.1 Pre-Filled Syringes: World Unit & Market Sales Forecasts, 2010-2025 [Ocultar lista de tablas / figuras] |
||||||||||||
| Precio ** (Formato del reporte): |
libre de costos de envio **Importante: Todos los precios son netos sin impuestos. Depende del país y de su tipo de empresa para pagar los impuestos. Si usted nos da su dirección de facturación, el monto total correcto será indicado en la siguiente orden de proceso. Para más información de impuestos y precios usted nos encuentra en nuestros FAQs |
|||||||||||
